Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation
Conclusion
High dose Valacyclovir is a potential alternative to Valganciclovir and Foscarnet in the stable post-HSCT patient who has cytopenia and is not keen for inpatient treatment of CMV antigenemia.
Source: BMC Hematology - Category: Hematology Source Type: research
More News: Cytomegalovirus | Hematology | Stem Cell Therapy | Stem Cells | Study | Transplants | Valtrex